Clinical trial Recruiting at 3 sites Phase 4 Interventional Ages 18 to 80

Simplified Tranexamic Acid Regimen for Trauma with Hemorrhage

Official title: Simplified Versus Divided-Dose Tranexamic Acid Regimen in Patients With Traumatic Hemorrhagic Shock: A Multicenter, Randomized, Open-Label Pilot Study

Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07869537 · Data updated 2026-11-12

This trial tests a simplified TXA dosing approach to see if it safely helps adults with major trauma and significant bleeding.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment60 (estimated)
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Academic / other
Locations3 sites (Hangzhou, Zhejiang and 2 other locations)
StatusRecruiting
StartedOctober 1, 2026
Main results expectedMarch 31, 2027
Study endsApril 30, 2027
Registry record updatedOctober 9, 2026
Trial IDNCT07869537 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with trauma and significant hemorrhage treated within 3 hours of injury who consent or meet emergency consent requirements.

Probably not a fit

Patients with contraindications to TXA, traumatic arrest on admission, high imminent death risk, or thrombotic history may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, interventional study evaluates a simplified tranexamic acid regimen in adult trauma patients with significant hemorrhage. The goal is to determine whether a streamlined TXA dosing protocol provides safe and effective hemostasis within the critical early hours after injury. Participants must be treated within 3 hours of injury and meet predefined criteria for severe bleeding or high risk of massive transfusion. Exclusion criteria include allergy to TXA, pregnancy, prior traumatic arrest with high short-term mortality risk, thrombotic history, epilepsy, unknown injury time, or prior TXA administration before admission. The study is led by the Second Affiliated Hospital, Zhejiang University School of Medicine, with several regional collaborators in Zhejiang Province, China.

Why it matters

Potential benefit: If successful, patients could experience improved control of bleeding with a potentially simpler TXA regimen.

How similar studies have gone: TXA has shown mortality reduction in traumatic bleeding in prior trials, supporting continued evaluation in simplified regimens.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years
* Trauma patients
* Significant hemorrhage (systolic blood pressure \<90 mm Hg or heart rate \>110 beats per min, or both) or clinical assessment of risk of massive transfusion (massive transfusion was defined as administration of at least 3 PRBC within the hour of admission or at least 10 PRBC within the first 24 hours)
* who were within 3 h of injury
* To obtain informed consent (or comply with the requirements for emergency exemptions agree)

Exclusion Criteria:

* Known to be allergic to TXA
* Pregnancy
* Traumatic cardiac arrest occurring prior to or at the time of admission, or patients with a high risk of death within 3 hours of admission
* History of thrombotic disease (such as DVT and PE, MI, stroke)
* History of epilepsy
* Injury time is unknown or \> 3 hours
* have received TXA before admission.

Where it's running

  • the Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
  • Jiaxing First Hospital
    Jiaxin, Zhejiang, China
    Recruiting
  • Third Affiliated Hospital, Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.